ACRV - Acrivon Therapeutics, Inc. Common Stock

Momentum: Bearish

Recent News

Here's Why Acrivon Therapeutics, Inc. ( ACRV ) Is a Great 'Buy the Bottom' Stock Now

Zacks Commentary • 4 months, 1 week ago • score: 0.39

Acrivon Therapeutics, Inc. (ACRV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of precision cancer medicines. The company is headquartered in Watertown, Massachusetts.

52W High

$10.00

52W Low

$1.05

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.67

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.43

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.36

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

20.64%

Institutions (25–75% balanced)

56.75%

Shares Outstanding

31,455,600

Float

16,683,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-2.24

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.48%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0837

0.0880

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025